Patents by Inventor Maria Alimova

Maria Alimova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS RELATED TO BICYCLO[2.2.1] HEPTANAMINE-CONTAINING COMPOUNDS
    Publication number: 20240116850
    Abstract: The present disclosure relates to compositions and methods related to bicyclo[2.2.1]heptanamine-containing compounds and salts thereof.
    Type: Application
    Filed: December 23, 2021
    Publication date: April 11, 2024
    Inventors: Brian T. Chamberlain, Florence F. Wagner, Maria Alimova, Anna Greka
  • Compositions and methods related to di-substituted bicyclo[2.2.1] heptanamine-containing compounds
    Patent number: 11840495
    Abstract: The present disclosure relates to compositions and methods related to bicyclo[2.2.1] heptanamine-containing compounds and salts.
    Type: Grant
    Filed: December 23, 2021
    Date of Patent: December 12, 2023
    Assignees: The Broad Institute, Inc., Instituto Carlos Slim de la Salud, A.C., Brigham and Women's Hospital, Inc.
    Inventors: Brian T. Chamberlain, David Kornfilt, Florence F. Wagner, Maria Alimova, Anna Greka, Joseph Growney
  • COMPOSITIONS AND METHODS RELATED TO DI-SUBSTITUTED BICYCLO[2.2.1] HEPTANAMINE-CONTAINING COMPOUNDS
    Publication number: 20220242815
    Abstract: The present disclosure relates to compositions and methods related to bicyclo[2.2.1] heptanamine-containing compounds and salts.
    Type: Application
    Filed: December 23, 2021
    Publication date: August 4, 2022
    Inventors: Brian T. Chamberlain, David Kornfilt, Florence F. Wagner, Maria Alimova, Anna Greka, Joseph Growney
  • AGENTS FOR REVERSING TOXIC PROTEINOPATHIES
    Publication number: 20220054433
    Abstract: The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of proteinopathies, particularly MUC1-associated kidney disease (ADTKD-MUC1 or MKD), Retinitis Pigmentosa (e.g., due to rhodopsin mutations), autosomal dominant tubulo-interstitial kidney disease due to UMOD mutation(s) (ADTKD-UMOD), and other forms of toxic proteinopathies resulting from mutant protein accumulation in the ER or other secretory pathway compartments and/or vesicles, among others. The disclosure also identifies and provides TMED9-binding agents as capable of treating or preventing proteinopathies of the secretory pathway, and further provides methods for identifying additional TMED9-binding agents.
    Type: Application
    Filed: October 5, 2021
    Publication date: February 24, 2022
    Applicants: THE BROAD INSTITUTE, INC., THE BRIGHAM & WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE, INC., Instituto Carlos Slim de la Salud, A.C.
    Inventors: Anna Greka, Moran Dvela-Levitt, Maria Alimova, Eric Lander, Todd R. Golub, Florence Wagner, Brian Chamberlain, Valeria Padovano, Joseph Growney
  • AGENTS FOR REVERSING TOXIC PROTEINOPATHIES
    Publication number: 20220023233
    Abstract: The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of proteinopathies, particularly MUC1-associated kidney disease (ADTKD-MUC1 or MKD), Retinitis Pigmentosa (e.g., due to rhodopsin mutations), autosomal dominant tubulo-interstitial kidney disease due to UMOD mutation(s) (ADTKD-UMOD), and other forms of toxic proteinopathies resulting from mutant protein accumulation in the ER or other secretory pathway compartments and/or vesicles, among others. The disclosure also identifies and provides TMED9-binding agents as capable of treating or preventing proteinopathies of the secretory pathway, and further provides methods for identifying additional TMED9-binding agents.
    Type: Application
    Filed: October 6, 2021
    Publication date: January 27, 2022
    Applicants: THE BROAD INSTITUTE, INC., THE BRIGHAM & WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE, INC., Instituto Carlos Slim de la Salud, A.C.
    Inventors: Anna Greka, Moran Dvela-Levitt, Maria Alimova, Eric Lander, Todd R. Golub, Florence Wagner, Brian Chamberlain, Valeria Padovano, Joseph Growney
  • Agents for reversing toxic proteinopathies
    Patent number: 11207278
    Abstract: The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of proteinopathies, particularly MUC1-associated kidney disease (ADTKD-MUC1 or MKD), Retinitis Pigmentosa (e.g., due to rhodopsin mutations), autosomal dominant tubulo-interstitial kidney disease due to UMOD mutation(s) (ADTKD-UMOD), and other forms of toxic proteinopathies resulting from mutant protein accumulation in the ER or other secretory pathway compartments and/or vesicles, among others. The disclosure also identifies and provides TMED9-binding agents as capable of treating or preventing proteinopathies of the secretory pathway, and further provides methods for identifying additional TMED9-binding agents.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: December 28, 2021
    Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Anna Greka, Moran Dvela-Levitt, Maria Alimova, Eric Lander, Todd R. Golub, Florence Wagner, Brian Chamberlain, Valeria Padovano, Joseph Growney
  • AGENTS FOR REVERSING TOXIC PROTEINOPATHIES
    Publication number: 20210169827
    Abstract: The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of proteinopathies, particularly MUC1-associated kidney disease (ADTKD-MUC1 or MKD), Retinitis Pigmentosa (e.g., due to rhodopsin mutations), autosomal dominant tubulo-interstitial kidney disease due to UMOD mutation(s) (ADTKD-UMOD), and other forms of toxic proteinopathies resulting from mutant protein accumulation in the ER or other secretory pathway compartments and/or vesicles, among others. The disclosure also identifies and provides TMED9-binding agents as capable of treating or preventing proteinopathies of the secretory pathway, and further provides methods for identifying additional TMED9-binding agents.
    Type: Application
    Filed: January 28, 2021
    Publication date: June 10, 2021
    Applicants: THE BROAD INSTITUTE, INC., THE BRIGHAM & WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE, INC., Instituto Carlos Slim de la Salud, A.C.
    Inventors: Anna Greka, Moran Dvela-Levitt, Maria Alimova, Eric Lander, Todd R. Golub, Florence Wagner, Brian Chamberlain, Valeria Padovano, Joseph Growney